Ignacio brings nearly a decade of senior leadership experience from the biopharma industry, primarily at GSK. As Sr. Business Manager for Vaccines and Specialties markets, he led strategic initiatives that positively impacted the lives of thousands of patients while delivering consistent double-digit growth. His expertise lies in go-to-market execution, stakeholder alignment, and high-performance team leadership. Ignacio holds a degree in Business Management from UCA and has completed executive education at the Kellogg and ESCP Business School. He is dedicated to bridging the gap between world-class scientific research and scalable clinical solutions to address urgent global health challenges like antimicrobial resistance (AMR). He is currently the CEO and co-founder of Resistia, where they are developing a therapeutic platform based on healthy microbiota to re-empower existing antibiotics and cure biofilm-resistant infections. Resistia is currently part of the Blueprint program by The Engine (MIT) and was recently selected as a pitching finalist at the 10th AMR Conference in Basel.